ClearEndoclip Versus EZ Clip for Upper Gastrointestinal Ulcer Bleeding
NCT ID: NCT04536428
Last Updated: 2020-09-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
176 participants
INTERVENTIONAL
2020-08-24
2021-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1\) Research hypothesis and purpose
* This study was designed to prove the hypothesis that the hemostatic effect of newly developed endoscopic clip (ClearEndoclip, FineMedix, Taegu, Korea) is not inferior to that of EZ clip (Olympus, Tokyo, Japan) in the treatment of hemostasis for patients who visited the upper gastrointestinal ulcer bleeding.
* This study was designed as a multi-center (9 institutions), open-labelled, randomized comparative clinical trial (1:1 ratio).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hemostatic Powder Following Injection Therapy Versus Conventional Dual Therapy for Endoscopic Hemostasis for Non-variceal Upper Gastrointestinal Bleeding
NCT02717416
The Use of OTSC in LBGDU to Standard Endoscopic Hemostatic Methods
NCT06196710
Resolution Endoclips Vs Epinephrine Injection and Heater Probe
NCT00165009
Role of Hemostatic Powder (Endo-clotTM) in Success and Prevention of Bleeding Within Gastric Cancer Patients With Bleeding
NCT02732483
The Clinical Feature of Ulcer Base Over Time After Prophylactic Argon Plasma Coagulation in Colonic EMR
NCT02025764
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Stratified randomization is performed, and the variable used for stratification is the patient's age (65 years or older, 65 years or less).
2. The existing clip (control) and the domestic clip (experimental group) are divided by the block size randomization method of size 4 for each floor.
2. Patients and Methods
1. inclusion criteria
* Men and women aged 20 to 80
* The patients who came to the emergency room due to upper gastrointestinal bleeding with as follows: peptic ulcer with acute bleeding or protruding vascular exposure (Forrest class Ia-IIa), anastomotic vascular ulcer bleeding, bleeding from endoscopic submucosal dissection or endoscopic mucosal resection site after 24 hours
* American Society of Anesthesiologist (ASA) Physical Status 1 - 3
* Patients with adequate patient compliance and adequate geographical distance for follow-up. character
2. exclusion criteria
* Patients with gastrointestinal bleeding who are not recommended to clip Bleeding from a malignant tumor Hemorrhagic gastritis Angiodysplasia variceal bleeding
* Bleeding during endoscopic submucosal dissection or endoscopic mucosal resection
* Patients with insufficient clinical information
* Pregnant or lactating patients
* Patients or guardians who have not obtained informed consent
3. The number of patients
* The number of subjects was calculated based on a non-inferiority study
* The reported rate of rebleeding after hemostasis using the conventional hemoclip: about 5%.
* 2.5% one-sided test, 80% power, and non-inferiority limit set to 10%
* 75 subjects are required for each group, and 83 subjects are required if the drop rate is assumed to be 10%.
4. Methods
* After completing an informed consent form to the subjects who wish to participate in the study at the time of visit, basic clinical variables are checked.
* First endoscopic hemostasis is performed. In this time, EZ clip is used for the subjects assigned to the control group, and ClearEndoclip is used for the subjects assigned to the experimental group to target blood vessels in the ulcer. At the same time, clinical parameters related to hemostasis are recorded.
* After hemostasis is performed, rebleeding and complications are tracked up to 30 days after the procedure.
5. Variables to be collected
* At the time of visit: age, gender, height, weight, drug use (anticoagulant/antiplatelet agents, NSAIDs, steroids), underlying diseases (cirrhosis, diabetes, end-stage renal failure, heart disease, lung disease), hematological data, hemoglobin, Complete Rockall score
* At the time of primary endoscopic hemostasis: location of ulcer, size of ulcer, size of exposed blood vessel (based on 2mm), forrest classification, total number of clips used, number of failed clips, usage and usage of epinephrine, procedure time (minutes) , Clip hemostasis success, treatment after clip hemostasis failure
* After hemostasis: rebleeding (within 7 days), number of clips and bleeding from the follow-up endoscope after 48 hours, death within 30 days, ICU hospitalization date, total hospitalization date, complications of hemostasis, Helicobacter pylori
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ClearEndoclip
This arm is a group in whom ClearEndoclip would be used for the treatment of bleeding.
Endoscopic hemostasis with clip
This intervention is performed as the following orders.
* The tip of endoscope is accessed to a bleeding site.
* The accurate visualization of bleeding site is done.
* A sheath of delivery system of clip is inserted through a working channel of endoscope.
* The end of clip is opened in front of the bleeding site. If needed, clip could be rotated to adjust to a bleeding target.
* The both ends of clip are placed on both sides of a bleeding site.
* If bleeding is still continued, additional placements of clip are tried until bleeding stops.
EZ clip
This arm is a group in whom EZ clip would be used for the treatment of bleeding.
Endoscopic hemostasis with clip
This intervention is performed as the following orders.
* The tip of endoscope is accessed to a bleeding site.
* The accurate visualization of bleeding site is done.
* A sheath of delivery system of clip is inserted through a working channel of endoscope.
* The end of clip is opened in front of the bleeding site. If needed, clip could be rotated to adjust to a bleeding target.
* The both ends of clip are placed on both sides of a bleeding site.
* If bleeding is still continued, additional placements of clip are tried until bleeding stops.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endoscopic hemostasis with clip
This intervention is performed as the following orders.
* The tip of endoscope is accessed to a bleeding site.
* The accurate visualization of bleeding site is done.
* A sheath of delivery system of clip is inserted through a working channel of endoscope.
* The end of clip is opened in front of the bleeding site. If needed, clip could be rotated to adjust to a bleeding target.
* The both ends of clip are placed on both sides of a bleeding site.
* If bleeding is still continued, additional placements of clip are tried until bleeding stops.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patients who came to the emergency room due to upper gastrointestinal bleeding with as follows: peptic ulcer with acute bleeding or protruding vascular exposure (Forrest class Ia-IIa), anastomotic vascular ulcer bleeding, bleeding from endoscopic submucosal dissection or endoscopic mucosal resection site after 24 hours
* American Society of Anesthesiologist (ASA) Physical Status 1 - 3
* Patients with adequate patient compliance and adequate geographical distance for follow-up. character
Exclusion Criteria
* Bleeding during endoscopic submucosal dissection or endoscopic mucosal resection
* Patients with insufficient clinical information
* Pregnant or lactating patients
* Patients or guardians who have not obtained informed consent
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Keimyung University Dongsan Medical Center
OTHER
Korea University Anam Hospital
OTHER
National Cancer Center, Korea
OTHER_GOV
Nowon Eulji Medical Center
UNKNOWN
Pusan National University Hospital
OTHER
Wonju Severance Christian Hospital
OTHER
Inha University Hospital
OTHER
Presbyterian medical center
UNKNOWN
Ajou University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sun Gyo Lim, MD
Associate professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sun Gyo Lim
Role: PRINCIPAL_INVESTIGATOR
Department of Gastroenterology, Ajou University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sun Gyo Lim
Suwon, Gyeonggi-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AJIRB-DEV-DE2-20-148
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.